Omada Health (OMDA) announced the planned launch of its prescribing capability, adding an option for prescribing and medication management of anti-obesity medications, including GLP-1s, to its weight health program. “Between provider visits is when real life happens and where outcomes are determined,1,2 and we believe Omada is uniquely positioned to offer support throughout the whole care journey,” said Thomas Tsang, chief medical officer at Omada Health. “This new capability will provide coordinated care as members start, stay on, or transition from AOMs. We also plan to continue enhancing this experience by building on our integration of AI-enabled support tools.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMDA:
- Omada Health reports Q3 EPS (6c), consensus (7c)
- Omada Health raises FY25 revenue view to $251.5M-$254.5M from $235M-$241M
- Omada Health to present RWE on behavior change program at ObesityWeek
- Omada Health, Inc.: Strategic Growth and Market Penetration Drive Buy Rating
- Omada Health appoints Tsang as Chief Medical Officer